Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New ...

As Cantor Fitzgerald analyst Carter Gould put it, Pfizer’s deal with 3SBio thrusts the company into the PD-1/VEGF race, but at “considerable” cost and “meaningfully behind” the competition.

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

The agreement also provides Pfizer the option of commercialization rights in China. 3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated ...

As Cantor Fitzgerald analyst Carter Gould put it, Pfizer's deal with 3SBio thrusts the company into the PD-1/VEGF race, but at "considerable" cost and "meaningfully behind" the competition.